Should I buy Option Care Health (OPCH) stock or is it too late?

Option Care Health · Health Care · price $24

See the full Option Care Health (OPCH) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stephens & Co. — 72% of its targets hit on this sector (39 calls tested). It aims for $24 (+0.1 %), call made on July 18, 2026, maturing on July 18, 2027 (41 d ago).

The 3 reliable analysts $24+0.1 %

The 5 other firms $33+38 %

How to read it: the 3 reliable firms are not filtered by optimism — 2 aim above the price, 1 below, hence their $24 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Option Care Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Barrington Research	38 %	-3.2 %	16	$32 +33%
JMP Securities	17 %	-9.1 %	6	$38 +58%

In short — Should you invest in Option Care Health? Is it too late, still worth it? Analysts are split (50% buy, median target $24, i.e. +0%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 8 ratings, only 4 buys, and the median price target ($24) is barely above the price (+0%, at $24). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on OPCH, Goldman Sachs (100% hit rate, 2 scored calls), only targets $22 (call made on June 8, 2026, maturing on June 8, 2027) (-8%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 8 ratings, 4 are neutral.
Limited upside: the median target is only +0% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on OPCH

Median target $24 (+0%) · 8 ratings · Buy consensus

Strong Buy00%

Buy450%

Hold450%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Option Care Health now?

We won't decide for you. The facts: 50% of analysts rate it a buy, median target $24 (+0%), and Goldman Sachs (most reliable on OPCH, 100%) targets $22. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Option Care Health?

The stated upside is small: the median target ($24) sits just +0% from the price ($24) (most reliable on OPCH: Goldman Sachs, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Option Care Health still worth investing in?

It depends on the gap between the price ($24) and its estimated value: analysts target $24 on median (+0%), with 50% buys (most reliable on OPCH: Goldman Sachs, 100%). Cross-check with their real reliability on OPCH and the cautions above. Information, not advice.

What's the main risk in buying OPCH?

Even the most reliable firm on OPCH, Goldman Sachs (100% hit rate, 2 scored calls), only targets $22 (call made on June 8, 2026, maturing on June 8, 2027) (-8%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Option Care Health profile (consensus, analyst reliability, price target, performance).